Literature DB >> 15057291

The evolution of thalidomide and its IMiD derivatives as anticancer agents.

J Blake Bartlett1, Keith Dredge, Angus G Dalgleish.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 15057291     DOI： 10.1038/nrc1323

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


× No keyword cloud information.
  206 in total

1.  The 5q- syndrome: biology and treatment.

Authors:  Eric Padron; Rami Komrokji; Alan F List
Journal:  Curr Treat Options Oncol       Date:  2011-12

2.  Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma.

Authors:  Jia Ruan; Peter Martin; Morton Coleman; Richard R Furman; Ken Cheung; Adam Faye; Rebecca Elstrom; Mark Lachs; Katherine A Hajjar; John P Leonard
Journal:  Cancer       Date:  2010-06-01       Impact factor: 6.860

3.  Tautomerism in drug discovery.

Authors:  Alan R Katritzky; C Dennis Hall; Bahaa El-Dien M El-Gendy; Bogdan Draghici
Journal:  J Comput Aided Mol Des       Date:  2010-05-20       Impact factor: 3.686

4.  Myelodysplastic syndromes--many new drugs, little therapeutic progress.

Authors:  Ayalew Tefferi
Journal:  Mayo Clin Proc       Date:  2010-09-22       Impact factor: 7.616

5.  Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.

Authors:  Jia Ruan; Peter Martin; Bijal Shah; Stephen J Schuster; Sonali M Smith; Richard R Furman; Paul Christos; Amelyn Rodriguez; Jakub Svoboda; Jessica Lewis; Orel Katz; Morton Coleman; John P Leonard
Journal:  N Engl J Med       Date:  2015-11-05       Impact factor: 91.245

6.  Combination therapy with lenalidomide and nanoceria ameliorates CNS autoimmunity.

Authors:  Erez Eitan; Emmette R Hutchison; Nigel H Greig; David Tweedie; Hasan Celik; Soumita Ghosh; Kenneth W Fishbein; Richard G Spencer; Carl Y Sasaki; Paritosh Ghosh; Soumen Das; Susheela Chigurapati; James Raymick; Sumit Sarkar; Srinivasulu Chigurupati; Sudipta Seal; Mark P Mattson
Journal:  Exp Neurol       Date:  2015-08-13       Impact factor: 5.330

Review 7.  The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors.

Authors:  James W Hodge; Andressa Ardiani; Benedetto Farsaci; Anna R Kwilas; Sofia R Gameiro
Journal:  Semin Oncol       Date:  2012-06       Impact factor: 4.929

8.  Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.

Authors:  Andrea Pellagatti; Martin Jädersten; Ann-Mari Forsblom; Helen Cattan; Birger Christensson; Emma K Emanuelsson; Mats Merup; Lars Nilsson; Jan Samuelsson; Birgitta Sander; James S Wainscoat; Jacqueline Boultwood; Eva Hellström-Lindberg
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-18       Impact factor: 11.205

Review 9.  Novel molecular pathways in Gorham disease: implications for treatment.

Authors:  Jeroen Hagendoorn; Torunn I Yock; Inne H M Borel Rinkes; Timothy P Padera; David H Ebb
Journal:  Pediatr Blood Cancer       Date:  2013-11-08       Impact factor: 3.167

10.  Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion.

Authors:  Maria Ximeri; Athanasios Galanopoulos; Mirjam Klaus; Agapi Parcharidou; Krinio Giannikou; Maria Psyllaki; Argyrios Symeonidis; Vasiliki Pappa; Zafiris Kartasis; Dimitra Liapi; Eleftheria Hatzimichael; Styliani Kokoris; Penelope Korkolopoulou; Constantina Sambani; Charalampos Pontikoglou; Helen A Papadaki
Journal:  Haematologica       Date:  2009-09-22       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.